[Clinical studies of aspoxicillin in pediatrics].
A clinical and laboratory evaluation and a blood level studied on aspoxicillin (ASPC), a new injectable penicillin derivative; the following results were obtained. ASPC was intravenously administered in 3 or 4 divided doses at a daily dosage ranging from 83.3 to 111.9 mg/kg to 5 patients (1 case of lacunar tonsillitis caused by H. influenzae, 3 cases of pneumonia caused by H. influenzae, 1 case of pneumonia caused by E. coli). As the results, a global effect were excellent in 3 cases and good in 2 cases. The overall efficacy ratio was 100%. All isolated organisms were eradicated, excluding the only case of pneumonia due to H. influenzae infection. No side effects were found in any of the 7 patients including 2 patients who were dropped out the efficacy evaluation because of Mycoplasma pneumonia. Laboratory findings showed a slight elevation of GOT and GPT in 2 cases and temporary eosinophilia in 1 case. Blood level of ASPC in 2 cases after 10 mg/kg administration by intravenous injection was 28.5 or 35.5 micrograms/ml at 30 minutes, 14.3 or 20.7 micrograms/ml at 1 hour, 6.1 or 8.8 micrograms/ml at 2 hours, 1.3 or 3.02 micrograms/ml at 4 hours. The half-life was 0.81 or 1.01 hours, respectively. Judging from the results of this blood level and the MIC of ASPC against clinically isolated organisms, good efficacy will be obtained to pediatric infections by the sensitive strains, if it is given 10 mg/kg to mild patients or 20 mg/kg to moderate or severe patients in 3 or 4 divided dose at a daily dosage.